Azurity Pharmaceuticals, a Massachusetts-based firm focused on the 505(b)(2) hybrid new drug application pathway, says it looks forward to bringing its commercial expertise to Slayback Pharma’s pipeline after acquiring the New Jersey-based 505(b)(2) and complex generics firm for an undisclosed fee.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?